A Phase I Study of the Safety, Tolerability, Pharmacokinetics Profiles and Preliminary Efficacy of 3D011-08 for Injection Monotherapy in Subjects With Advanced Solid Tumors

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 05 Feb 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs 3D011-08 (Primary)
Indications Liver cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors 3D Medicines

30 Jan 2024 Planned End Date changed from 31 Dec 2023 to 11 Sep 2023.
30 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 11 Sep 2023.
30 Jan 2024 Planned initiation date changed from 1 Feb 2022 to 24 Feb 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com